Latest News and Press Releases

WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information...

WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral...

Brilacidin showed potent inhibition in multiple human cell lines and in different strains of alphaviruses and bunyaviruses, building on earlier antiviral work in coronavirusesThese data collectively...

Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE)...

WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the...

WAKEFIELD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form...

>60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trialWith COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than...

WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the...

Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of virusesBrilacidin is currently undergoing Phase 2 clinical testing against COVID-19 in hospitalized...